BioBridgeX
Log inCompare quotes
Indication

Gastroenterology / Hepatology CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a gastroenterology or hepatology program means hiring CROs and CDMOs for GI and liver disease work: IBD and colitis models, fibrosis and NASH studies, gut-microbiome assays, endoscopy and biopsy-driven endpoints, and clinical sites that can recruit confirmed IBD, cirrhosis, or hepatitis patients. On BioBridgeX, buyers source and compare vetted suppliers as the neutral marketplace, free for buyers, and contract directly with the supplier they choose.

Gastroenterology / Hepatology CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Gastroenterology / Hepatology CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Gastroenterology / Hepatology program need?

GI and liver programs lean hard on disease models that behave differently from a generic toxicology line, so the first thing you are buying is biology that actually mirrors the clinic. For inflammatory bowel disease, that usually means chemically induced colitis (DSS or TNBS), adoptive-transfer or IL-10 knockout models, and increasingly patient-derived intestinal organoids and gut-on-a-chip systems that let you read barrier function and inflammation without an animal. For liver, the work splits between fibrosis (CCl4, bile-duct ligation, thioacetamide), diet-induced steatohepatitis for NASH and the newer MASH naming, and precision-cut liver slices or primary hepatocyte work for mechanism and metabolism. Microbiome programs add a layer most CROs are not set up for: germ-free and gnotobiotic husbandry, 16S and shotgun sequencing, metabolomics on short-chain fatty acids and bile acids, and the bioinformatics to make sense of it.

Discovery and preclinical services here look familiar on the surface (target validation, assay development, screening, PK/PD, GLP toxicology) but the readouts are indication-specific. You care about histology scored by a GI pathologist (Geboes or Nancy index for colitis, NAS and fibrosis staging for liver), gut permeability assays, fecal calprotectin and lipocalin, transaminases and liver-function panels, and where relevant the FXR, TGR5, and bile-acid pathways that drive a lot of current hepatology chemistry. A supplier that has only run oncology efficacy work will not know which of these endpoints a reviewer expects.

On the clinical side, gastroenterology and hepatology are recruitment-heavy. Trials hinge on endoscopy with central reading, biopsy collection and handling, and biomarker logistics that a generalist site network often fumbles. IBD studies need confirmed Crohn's or ulcerative colitis patients with scored endoscopic disease at baseline; NASH and cirrhosis trials need biopsy-confirmed or, increasingly, FibroScan and MRI-PDFF-staged patients, which narrows the eligible pool sharply. A CRO with real GI and hepatology sites, hepatologist investigators, and central endoscopy reading experience will save you months that a broad-spectrum CRO spends learning the disease.

How do you choose a CRO for Gastroenterology / Hepatology?

The honest filter is whether the group has done your specific GI or liver work before, not whether they have a slide that says they cover the therapeutic area. A team that runs flawless DSS colitis may have never staged a fibrosis model, and a clinical CRO with strong oncology sites can be weak on IBD recruitment. Score two or three suppliers against the same written scope using the checklist below, and ask to speak with the scientists or medical monitor who would actually run your program.

  • Therapeutic-area experience: ask for named GI and hepatology programs they have run (IBD, NASH/MASH, fibrosis, cirrhosis, GI motility), and confirm the people on your project did that work, not a different team at the same company.
  • Relevant disease models or patient access: for preclinical, confirm they run the specific model you need (DSS, TNBS, adoptive transfer, CCl4, bile-duct ligation, diet-induced NASH, gnotobiotic microbiome work) with established historical control data; for clinical, confirm sites and investigators that recruit confirmed IBD or biopsy/elastography-staged liver patients.
  • Endpoint and pathology depth: check that histology is read by a GI or liver pathologist using accepted scoring (Geboes, Nancy, NAS, fibrosis stage), and that they handle indication-specific biomarkers (calprotectin, transaminases, bile acids, FibroScan, MRI-PDFF) correctly.
  • Regulatory track record: ask for IND-enabling packages and submissions in GI or hepatology specifically, GLP status for the tox work, and familiarity with FDA and EMA expectations for these indications (the MASH endpoint guidance, for instance, has shifted recently).
  • Data quality and traceability: look for documented SOPs, qualified assays with performance data, central reading for endoscopy and imaging, clean audit-ready data capture, and reference programs you can actually call.
  • Capacity and lead time: germ-free suites, biopsy-capable sites, and central endoscopy readers are genuinely scarce, so confirm the real queue and turnaround rather than the brochure timeline, since a booked specialist can be slower than an open generalist who then has to learn the disease.

Frequently asked questions

What CRO services does an IBD or ulcerative colitis program actually need?
Preclinically, you need validated colitis models (DSS and TNBS are the workhorses, with adoptive transfer or IL-10 knockout for more chronic immune-driven disease), increasingly backed by patient-derived intestinal organoids or gut-on-a-chip for human-relevant readouts. The endpoints that matter are histology scored by a GI pathologist using Geboes or the Nancy index, plus gut permeability, calprotectin, and cytokine panels. Clinically, the constraint is patients: you need sites that recruit confirmed Crohn's or ulcerative colitis cases with endoscopically scored disease at baseline, and central endoscopy reading. A CRO with real IBD experience knows this; a generalist learns it on your budget.
How do I find a CRO with NASH, MASH, or liver fibrosis experience?
Look for named liver programs, not a therapeutic-area checkbox. On the preclinical side, ask which fibrosis and steatohepatitis models they run (diet-induced NASH, CCl4, bile-duct ligation, thioacetamide), whether they have historical control data for those models, and whether histology is staged by a liver pathologist using NAS and fibrosis scoring. On the clinical side, the field has moved toward biopsy-confirmed or FibroScan and MRI-PDFF-staged enrollment, and the regulatory endpoint expectations for MASH have changed, so confirm the team is current. On BioBridgeX you can filter suppliers that list hepatology experience and compare them against the same scope.
Do I need a specialized CRO for gut microbiome studies?
Usually yes, because the infrastructure is uncommon. Germ-free and gnotobiotic animal husbandry requires dedicated isolators and trained staff that most general preclinical CROs do not have. Beyond the animals, you need 16S and shotgun metagenomic sequencing, metabolomics for short-chain fatty acids and bile acids, and bioinformatics that can actually interpret the data rather than just generate it. If your program rests on a microbiome mechanism, vet that capability directly and ask to see prior gnotobiotic work, rather than assuming a CRO that lists gastroenterology covers it.
What does outsourcing a gastroenterology or hepatology program typically cost?
It varies too much to quote a single figure honestly, because a focused colitis efficacy study and a multi-site biopsy-confirmed NASH trial are different orders of magnitude. The cost drivers worth scoping separately are the disease model complexity (a simple DSS study versus a chronic fibrosis model with serial sampling), the depth of histopathology and biomarker work, and on the clinical side the recruitment difficulty, since biopsy-confirmed or elastography-staged patients are scarce and screen-fail rates run high. Scope each milestone with go/no-go gates and compare quotes from two or three qualified suppliers before committing. BioBridgeX is free for buyers, so comparing does not cost you anything.
How is BioBridgeX free for buyers if it makes money?
BioBridgeX charges the supplier a flat 2% fee on work that gets contracted through the platform, not the buyer. You source suppliers, compare qualified CROs and CDMOs, and contract without paying a platform fee. BioBridgeX acts as the neutral marketplace, which is also what lets you compare several suppliers and contract directly with each one you choose, all in one place. The model works across all indications and modalities, so a gastroenterology buyer and a hepatology buyer use the same flow.
Can I compare and contract directly with different suppliers for preclinical and clinical work in one place?
Yes, and that is much of the point of contracting through BioBridgeX. A GI or liver program often spans a preclinical CRO for the disease models and tox, a specialist for microbiome or histopathology, and a clinical CRO with the right sites. Normally that means three separate contracts, POs, and invoices to negotiate and chase. As the neutral marketplace, BioBridgeX lets you compare those suppliers and contract directly with each one in one place, which removes a lot of the procurement overhead while you still choose each supplier on its own merits.

Source Gastroenterology / Hepatology work with one contract

Compare transparent quotes from qualified Gastroenterology / Hepatology CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes